Thursday, November 1, 2012
Publication and contact
growth factor receptor 1 (EGFR1;
In vitro and mouse studies suggest inhibiting AREG-EGFR1
signaling could help treat idiopathic pulmonary fibrosis (IPF). In the lungs
of patients with IPF, TGFB1 levels were greater than those in lungs of
healthy individuals. In a mouse fibroblast cell line, human and mouse TGFB1
upregulated Areg, which activated Egfr1 and increased proliferation compared
with vehicle. In a transgenic TGFB1-expressing mouse model of
pulmonary fibrosis, AREG small interfering RNA or an EGFR1 inhibitor
decreased collagen accumulation and pulmonary fibrosis compared with a
scrambled siRNA or vehicle. Ongoing work includes investigating expression of
AREG in serum and tissues from patients with IPF and other fibrotic diseases.
At least 16 companies market inhibitors of EGFR
or EGFR1 to treat various cancers.
Published online Nov. 1, 2012
Patented by Yale University and Bioneer
Corp.; available for licensing
Zhou, Y. et al. J. Biol.
Chem.; published online Oct. 19, 2012;
Contact: Chun Geun Lee, Yale School of Medicine, New Haven,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]